Anagrelide
Indication :
Dosing :
0.5 mg-2 mg in 4 divided doses orally.
Adverse Effect :
Headache, palpitations, diarrhea, edema, nausea, abdominal pain, dizziness, dyspnea, vomiting, gaseous distention, chest pain, rash, edema, fever, tachycardia, back pain, itching, interstitial lung disease, hepatotoxicity, SVT, pulmonary hypertension, bleeding.
Renal Dose :
Dose in Renal Impairment GFR (mL/min)
| 30-50 | Dose as in normal renal function |
| 10-30 | Dose as in normal renal function, but use with caution and keep to lowest dose possible |
| <10 | Dose as in normal renal function, but use with caution and keep to lowest dose possible |
Dose in Patients undergoing Renal Replacement Therapies
| CAPD | Unknown dialysability. Dose as in GFR<10 mL/min |
| HD | Unknown dialysability. Dose as in GFR<10 mL/min |
| HDF/High flux | Unknown dialysability. Dose as in GFR<10 mL/min |
| CAV/VVHD | Unknown dialysability. Dose as in GFR=10–30 mL/min |
Hepatic Dose :
The major route of elimination of anagrelide is through hepatic metabolism.
Mild hepatic impairment: Assess the risk: benefit ratio before using the drug. Initial dose should be 0.5 mg PO OD. After one week, increase the dose by 0.5 mg. Weekly increase in the dose as per clinical response.
Moderate to severe hepatic impairment: Use is contraindicated.
The potential risks and benefits of anagrelide therapy in patients with mild or moderate hepatic impairment should be assessed before treatment begins.